Mobocertinib Dose Rationale in Patients With Metastatic NSCLC With EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.2622
Abstract: Mobocertinib is an oral tyrosine kinase inhibitor approved for treatment of patients with locally advanced or metastatic non-small cell lung cancer (mNSCLC) with epidermal growth factor receptor gene (EGFR) exon 20 insertion (ex20ins) mutations previously… read more here.
Keywords: molar sum; response; egfr exon; exposure ... See more keywords